UroGen Pharma Ltd. (URGN) Net income 2016–2025
UroGen Pharma Ltd. (URGN) annual net income history from SEC filings — each fiscal year as reported, with year-over-year change.
-$153.5MFY2025 · since FY2016: -$1.9M → -$153.5M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$153.5M | -21.0% |
| FY2024 | -$126.9M | -24.1% |
| FY2023 | -$102.2M | +6.9% |
| FY2022 | -$109.8M | +0.9% |
| FY2021 | -$110.8M | +13.7% |
| FY2020 | -$128.5M | -22.2% |
| FY2019 | -$105.1M | -39.0% |
| FY2018 | -$75.7M | -278.3% |
| FY2017 | -$20.0M | -930.4% |
| FY2016 | -$1.9M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More URGN financial trends
URGN RevenueURGN Net marginURGN Gross profitURGN Gross marginURGN Operating incomeURGN Operating marginURGN Operating cash flowURGN Free cash flowURGN Capital expendituresURGN Return on equityURGN Stock buybacksURGN Dividends paidURGN Total assetsURGN Total liabilitiesURGN Shareholders’ equityURGN overview →